These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1689895)

  • 1. Infections with FK 506 immunosuppression: preliminary results with primary therapy.
    Alessiani M; Kusne S; Martin FM; Fung JJ; Jain A; Todo S; Simmons R; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):44-6. PubMed ID: 1689895
    [No Abstract]   [Full Text] [Related]  

  • 2. Early infections in kidney transplant recipients under FK 506.
    Kusne S; Martin M; Shapiro R; Jordan M; Fung J; Alessiani M; Jain A; Todo S; Starzl T
    Transplant Proc; 1991 Feb; 23(1 Pt 2):956-7. PubMed ID: 1703364
    [No Abstract]   [Full Text] [Related]  

  • 3. Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls.
    Fung JJ; Todo S; Tzakis A; Demetris A; Jain A; Abu-Elmaged K; Alessiani M; Starzl TE
    Transplant Proc; 1991 Feb; 23(1 Pt 1):14-21. PubMed ID: 1703682
    [No Abstract]   [Full Text] [Related]  

  • 4. A cost comparison of liver transplantation with FK 506 or CyA as the primary immunosuppressive agent.
    Staschak S; Wagner S; Block G; Van Thiel DH; Jain A; Fung J; Todo S; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):47-9. PubMed ID: 1689896
    [No Abstract]   [Full Text] [Related]  

  • 5. Infections in adult liver transplant patients under FK 506 immunosuppression.
    Alessiani M; Kusne S; Martin M; Jain A; Abu-Elmagd K; Moser J; Todo S; Fung J; Starzl T
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1501-3. PubMed ID: 1703345
    [No Abstract]   [Full Text] [Related]  

  • 6. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy.
    Takaya S; Duquesnoy R; Iwaki Y; Demetris J; Yagihashi A; Bronsther O; Iwatsuki S; Starzl TE
    Transplant Proc; 1991 Feb; 23(1 Pt 1):396-9. PubMed ID: 1703691
    [No Abstract]   [Full Text] [Related]  

  • 7. Current status of FK 506 in liver transplantation.
    Fung JJ; Todo S; Tzakis A; Alessiani M; Abu-Elmagd K; Jain A; Bronster O; Martin M; Gordon R; Starzl TE
    Transplant Proc; 1991 Jun; 23(3):1902-5. PubMed ID: 1712133
    [No Abstract]   [Full Text] [Related]  

  • 8. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation.
    Fisher RA; Stone JJ; Wolfe LG; Rodgers CM; Anderson ML; Sterling RK; Shiffman ML; Luketic VA; Contos MJ; Mills AS; Ferreira-Gonzalez A; Posner MP
    Clin Transplant; 2004 Aug; 18(4):463-72. PubMed ID: 15233827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients.
    Mieles L; Gordon RD; Mintz D; Toussaint RM; Imventarza O; Starzl TE
    Transplant Proc; 1991 Feb; 23(1 Pt 2):949-53. PubMed ID: 1703362
    [No Abstract]   [Full Text] [Related]  

  • 10. FK 506--an investigational immunosuppressant.
    Med Lett Drugs Ther; 1991 Oct; 33(854):94. PubMed ID: 1716722
    [No Abstract]   [Full Text] [Related]  

  • 11. FK 506 and orthotopic liver transplantation in the rat.
    Isai H; Painter DM; Sheil AG
    Transplant Proc; 1990 Oct; 22(5):2125-6. PubMed ID: 1699329
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical use of FK 506 in liver transplantation.
    Klintmalm GB
    Transplant Proc; 1996 Apr; 28(2):974-6. PubMed ID: 8623484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506.
    Jain AB; Fung JJ; Todo S; Alessiani M; Takaya S; Abu-Elmagd K; Tzakis A; Starzl TE
    Transplant Proc; 1991 Feb; 23(1 Pt 2):928-30. PubMed ID: 1703354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transplantation's newest weapon FK 506.
    Pezze JL; Whiteman K
    Am J Nurs; 1991 Oct; 91(10):40-2. PubMed ID: 1716857
    [No Abstract]   [Full Text] [Related]  

  • 15. A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation.
    Armitage JM; Kormos RL; Griffith BP; Hardesty RL; Fricker FJ; Stuart RS; Marrone GC; Todo S; Fung J; Starzl TE
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1149-52. PubMed ID: 1703336
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug-drug interaction between chloramphenicol and tacrolimus in a liver transplant recipient.
    Taber DJ; Dupuis RE; Hollar KD; Strzalka AL; Johnson MW
    Transplant Proc; 2000 May; 32(3):660-2. PubMed ID: 10812156
    [No Abstract]   [Full Text] [Related]  

  • 17. Changing trends in infectious disease in heart transplantation.
    Haddad F; Deuse T; Pham M; Khazanie P; Rosso F; Luikart H; Valantine H; Leon S; Vu TA; Hunt SA; Oyer P; Montoya JG
    J Heart Lung Transplant; 2010 Mar; 29(3):306-15. PubMed ID: 19853478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FK 506--a promise of good things to come?
    Neuberger J
    Hepatology; 1991 Jun; 13(6):1259-60. PubMed ID: 1711005
    [No Abstract]   [Full Text] [Related]  

  • 19. Pancreaticoduodenal allotransplantation with FK 506 in the dog.
    Morimoto T; Yamada F; Kobayashi T; Miyaishi S; Tokumaru T; Kamiya I; Takagi H
    Transplant Proc; 1990 Apr; 22(2):717-9. PubMed ID: 1691550
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of splenectomy in combination with FK 506 and 15-deoxyspergualin on cardiac xenograft survival.
    Carobbi A; Araneda D; Patselas T; Thomas J; Mosca F; Thomas F
    Transplant Proc; 1991 Feb; 23(1 Pt 1):549-50. PubMed ID: 1703704
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.